All Publications


  • External validation and clinical implementation of clinical prediction models: a systematic review. Journal of the American Medical Informatics Association : JAMIA Suh, E. J., Kang, J. S., McDermott, J., Nelson, A. H., Kim, Y., Liu, J., Shah, K., Yu, B., Zhang, B., Lim, S. B., Choi, J. 2026

    Abstract

    To assess whether external validation and clinical implementation of clinical prediction models reflect sequential or distinct stages of a translational pathway.This cross-sectional meta-epidemiologic study analyzed 1072 machine learning-based clinical prediction models published across clinical domains (2017-2019). We assessed downstream external validation and clinical implementation via citation screening through August 2025. Evaluated exposures included public code availability, TRIPOD adherence, multicenter design, and sample size. Secondary outcomes included investigator overlap.Among 1072 studies, 88.1% lacked translational follow-up. Only 9.9% underwent external validation, and 5.2% reached clinical implementation. Code availability (odds ratio [OR] 3.04; 95% CI, 1.91-4.84) and higher TRIPOD adherence (OR 2.68 per 10% increase; 95% CI, 2.04-3.52) were significantly associated with external validation, but not consistently with clinical implementation. Notably, 39% of implemented models lacked prior external validation. Independent groups predominantly conducted external validation (72.6%), whereas implementation frequently involved original development teams.Findings indicate a divergence in algorithmic translation. Characteristics emphasizing evaluability (code availability, reporting transparency) facilitate external validation but do not ensure clinical implementation. The frequent bypass of independent validation before implementation highlights a reliance on institutional and operational factors rather than generalizable methodology.External validation and clinical implementation appear to represent distinct translational processes rather than sequential stages influenced by a uniform set of factors. Current practices facilitate validation but inadequately address operational requirements for real-world deployment.

    View details for DOI 10.1093/jamia/ocag182

    View details for PubMedID 42962244

  • Development and evaluation of a surgical approach for sheath-preserving optic nerve transection in rabbits Nelson, A., Jang, K., Rajpal, S., Rutigliani, C., Han, A., Manche, A., Jeon, H., Myung, D. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2026
  • Crystalline Lens Regeneration: A Review CURRENT OPHTHALMOLOGY REPORTS Nelson, A., Logan, C., Manche, A., Myung, D. 2026; 14 (1)
  • Development of Antimicrobial Nitric Oxide-Releasing Fibers. Pharmaceutics Wang, D. C., Clark, J. R., Lee, R., Nelson, A. H., Maresso, A. W., Acharya, G., Shin, C. S. 2021; 13 (9)

    Abstract

    Nitric oxide (NO) is a highly reactive gas molecule, exhibiting antimicrobial properties. Because of its reactive nature, it is challenging to store and deliver NO efficiently as a therapeutic agent. The objective of this study was to develop NO-releasing polymeric fibers (NO-fibers), as an effective delivery platform for NO. NO-fibers were fabricated with biopolymer solutions of polyvinyl pyrrolidone (PVP) and ethylcellulose (EC), and derivatives of N-diazeniumdiolate (NONOate) as NO donor molecules, using an electrospinning system. We evaluated in vitro NO release kinetics, along with antimicrobial effects and cytotoxicity in microorganisms and human cell culture models. We also studied the long-term stability of NONOates in NO-fibers over 12 months. We demonstrated that the NO-fibers could release NO over 24 h, and showed inhibition of the growth of Pseudomonas aeruginosa (P. aeruginosa) and methicillin-resistant Staphylococcus aureus (MRSA), without causing cytotoxicity in human cells. NO-fibers were able to store NONOates for over 12 months at room temperature. This study presents the development of NO-fibers, and the feasibility of NO-fibers to efficiently store and deliver NO, which can be further developed as a bandage.

    View details for DOI 10.3390/pharmaceutics13091445

    View details for PubMedID 34575520

    View details for PubMedCentralID PMC8468281